Redefining Therapeutic Delivery

At Tozho, we are advancing a new frontier in regenerative medicine through the development of engineered extracellular vesicle (EV) therapeutics. EVs are nanoscale, membrane-bound vesicles naturally secreted by cells, playing a vital role in intercellular communication by transporting proteins, mRNAs, and signaling molecules. Unlike traditional cell therapies, EVs offer a cell-free alternative that is biocompatible, less immunogenic, and highly scalable.

Our approach begins with mesenchymal stem cells (MSCs), known for their regenerative and immunomodulatory properties. We bioengineer MSC-derived EVs to enhance their therapeutic potency and persistence in hostile microenvironments, such as chronic, non-healing wounds. Specifically, we encapsulate the pro-angiogenic enzyme thymidine phosphorylase (TP) within EVs to stimulate new blood vessel formation. Additionally, we functionalize the EV surface with CD47, a “don’t-eat-me” signal that allows EVs to evade macrophage-mediated clearance—extending their therapeutic window and increasing efficacy.

To overcome the challenges of EV scalability and purity, Tozho has developed a proprietary chitin nanoparticle-based isolation platform that enables high-yield, GMP-adaptable EV production. Our system utilizes serum-free media supplemented with microalgal extracts, further enhancing MSC proliferation and vesicle output while maintaining clinical-grade standards.

By combining immune-evasive design, targeted bioactivity, and scalable manufacturing, Tozho is creating a platform capable of delivering transformative therapies for chronic wounds and beyond. Our science is grounded in precision biology and driven by the belief that smarter healing is possible—without relying on whole cells or systemic drug exposure. Tozho’s innovations position it at the forefront of EV-based regenerative medicine, with a pipeline focused on solving some of the most intractable challenges in tissue repair and recovery.